Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case

2016 ◽  
Vol 23 (10) ◽  
pp. 767-779 ◽  
Author(s):  
S. Deuffic-Burban ◽  
D. Obach ◽  
V. Canva ◽  
S. Pol ◽  
F. Roudot-Thoraval ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Budget Impact ◽  
Hepatitis C Treatment ◽  
Direct Acting Antiviral ◽  
French Case ◽  
Direct Acting

scholarly journals Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era

2020 ◽  
Vol 40 (10) ◽  
pp. 2407-2416
Author(s):  
Oluwaseun Falade‐Nwulia ◽  
Rachel E. Gicquelais ◽  
Jacquie Astemborski ◽  
Sean D. McCormick ◽  
Greg Kirk ◽  
...  
Keyword(s):  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Hepatitis C Treatment ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Direct Acting

scholarly journals Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany

2020 ◽  
Vol 17 (2) ◽  
pp. 440
Author(s):  
Melanie Runge ◽  
Magdalene Krensel ◽  
Claudia Westermann ◽  
Dominik Bindl ◽  
Klaus Nagels ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Base Case ◽  
German Statutory Accident Insurance ◽  
Direct Acting Antiviral ◽  
Life Years ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Around 1% of the world’s population is infected with hepatitis C. The introduction of new direct-acting antiviral agents (DAAs) in 2014 has substantially improved hepatitis C treatment outcomes. Our objective was to evaluate the long-term cost effectiveness of DAAs in health care personnel (HP) with confirmed occupational diseases in Germany. A standardised database from a German statutory accident insurance was used to analyse the cost-effectiveness ratio for the DAA regimen in comparison with interferon-based triple therapies. Taking account of the clinical progression of the disease, a Markov model was applied to perform a base case analysis for a period of 20 years. The robustness of the results was determined using a univariate deterministic sensitivity analysis. The results show that treatment with DAAs is more expensive, but also more effective than triple therapies. The model also revealed that the loss of 3.23 life years can be averted per patient over the 20 years. Compared to triple therapies, DAA treatment leads to a higher sustained virologic response (SVR). Although this results in a decrease of costs in the long term, e.g., pension payments, DAA therapy will cause greater expense in the future due to the high costs of the drugs.

Sign in / Sign up

Export Citation Format

Share Document